Sartorius Stedim Biotech completed the acquisition of Danaher Select Life Science Platform Businesses for $825m.

Sartorius Stedim Biotech, a provider of cutting-edge products and services for the development, quality assurance and production processes of the biopharmaceutical industry, completed the acquisition of Danaher's Select Life Science Platform Businesses, which provide chromatography hardware and resins, for $825m. “The portfolio proposed for acquisition represents an excellent strategic fit with Sartorius Stedim Biotech. With the chromatography hardware and resins and the microcarrier businesses, we broaden our strong bioprocessing offering, particularly in the downstream area. We look very much forward to welcoming the new teams to Sartorius and to jointly combine our capabilities for the benefit of our biopharma and life science customers,” Joachim Kreuzburg, Sartorius Stedim Biotech Chairman of the Board and CEO.